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Twenty patients with torticollis had electromyographic studies of their neck muscles performed before and after a 
series of local injections of botulinum toxin. The pattern of muscle activity changed after the injections, and this effect 
persisted even after head position had returned to baseline. Patients who did not experience any clinical benefit from 
the injections also demonstrated a change in the pattern of muscle activity. These results suggest that the underlying 
abnormality in torticollis usually involves a general motor program for head position, rather than the activity of 
individual neck muscles. 
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Local injections of botulinum toxin are effective in 
treating torticollis [ 1-81. The beneficial effects are 
temporary, typically fading after 1 to 3 months. In an 
earlier study 181, some of our patients reported that 
their symptoms had returned to baseline even though 
originally prominent muscles had become flaccid after 
injection. This suggested that the same abnormal head 
posture was now being produced by a different pattern 
of muscle activity. This possibility would be consistent 
with what is currently known about neck movements 
in normal subjects. 
The control system for neck movement has been 
called overcomplete, or overspecified, in that there are 
many more muscles available than necessary to accom- 
plish the required movements ~3, 101. Because of this 
feature, any given neck movement could in principle 
be produced by a large number of different patterns 
of muscle activity 11 11. Theoretical models have been 
developed to explain how the nervous system might 
“choose” from among the large number of possibilities 
19, 121, and experimental studies have demonstrated 
that for any particular task, each neck muscle partici- 
pates in an identifiable and repeatable manner [lo, 131. 
Thus, despite the overcomplete nature of the system, 
the same pattern of neck muscle activity is observed 
whenever an animal is required to achieve a given head 
position while performing a given task. By varying the 
task, however, a different pattern of neck muscle activ- 
ity may be seen to produce the same head position. 
This has been demonstrated by comparing reflex and 
voluntary neck movements in cats [lo], and by varying 
the force against which human subjects were required 
to stabilize their head position {lo, 131. 
Based on these experimental results, one could pre- 
dict that injection of botulinum toxin into neck muscles 
of a normal subject would result in a new pattern of 
muscle activity for any given head position. It is diffi- 
cult to predict what would occur in a patient with torti- 
collis, however, because the pathogenesis of torticollis 
is not understood. If torticollis is due to an abnormal 
motor program, then one might predict that a new 
pattern of muscle activity would emerge to produce 
the same abnormal head position despite the injection 
of botulinum toxin into previously overactive muscles. 
On the other hand, if torticollis is due to a relatively 
selective overactivity of individual neck muscles, then 
no persistent change in the pattern of muscle activity 
following botulinum toxin injections would be ex- 
pected. 
These two alternatives have significant implications, 
both for understanding the pathophysiology of torticol- 
lis and for predicting the likelihood of persistent clini- 
cal benefit from local injections of botulinum toxin. 
We decided to investigate this issue by directly com- 
paring the pattern of muscle activity before and after 
injections of botulinum toxin. 
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Materials and Methods 
The treatment design was similar to that used in our earlier 
study @I, but involved a different group of patients. 
Patients 
Twenty-two patients, 13 women and 9 men, were enrolled 
in the study. Two patients dropped out of the study because 
they observed no benefit from the injections, and experi- 
enced mild dysphagia; 1 of these patients had completed only 
one injection session and the other had completed mo. 
These patients were considered to be treatment failures in 
our analysis of clinical response rates, but they were not in- 
cluded in our analysis of electromyogrdphic (EMG) changes. 
The mean age of the 20 patients who completed the study 
was 54 years (range, 36 to 70 years), and the mean duration 
of illness was 8.4 years (range, 1 to 23 years). As in our 
previous study, patients were given the option of stopping 
all medications 1 month before entering the study or continu- 
ing on their current drug regimen without making any 
changes during the course of the study; all but 1 chose to do 
the latter. 
Injections 
The muscles that were thought to be most actively contribut- 
ing to the abnormal head position, either because they were 
tense in the resting position on clinical examination or be- 
cause EMG testing demonstrated an abnormal interference 
pattern, were selected for injection. These were chosen from 
among three pairs of muscles: the sternocleidomastoid, trape- 
zius, and splenius capitis muscles on each side. Most patients 
had either three or four muscles injected; 3 patients had five 
muscles injected, 1 patient had only two muscles injected, 
and 1 patient had all six muscles injected. Toxin was injected 
into two to eight sites per muscle, distributed evenly along 
the length of the muscle. Tsui (personal communication, 
1987). had previoilsly determined that injecting one or two 
sites near the middle of the muscle achieved the same effect 
as injecting multiple sites throughout the length of the mus- 
cle. We chose to inject multiple sites because it permitted a 
smaller volume per injection site, minimizing patient discom- 
fort. The same muscles and injection sites were used at all 
sessions for any given patient. There were four injection ses- 
sions for each patient. At one session the patient received 
placebo (saline solution), and at the others the patient re- 
ceived three different doses of botulinum toxin: a base total 
dose of 120 to 140 units, and half and twice this base dose. 
At no session did any patient receive more than a total of 
280 units, or 180 units to any one muscle. 
Injection Schedule 
For each patient, the four injection sessions (one placebo, 
three different doses of toxin) occurred in random order 
known to some of the investigators but not the patient or 
the electromyographer. After each injection session, the pa- 
tient was seen every 4 weeks, and not reinjected until any 
benefit (either subjective or objective; see below) from the 
preceding injection had completely disappeared. 
Clinical Eealuation 
SUBJECTIVE. At each clinic visit, patients were asked to rate 
separately the degree of pain and the severity of the head 
movements they had been experiencing, using a scale of 1 
to 10 for each, with a score of 5 being arbitrarily designated 
as the baseline state on entering the study. These two scores 
were then summed to provide a composite subjective scale. 
As in our previous study, changes from baseline of greater 
than 20% were considered to be “substantial.” 
OBJECTIVE. Patients were videotaped at the time they en- 
tered the study and 4 weeks after each injection session, 
following the standard filming protocol described in our pre- 
vious paper. The videotapes were rearranged in random or- 
der by the photographer after completion of the study and 
scored independently by the investigators, who were thus 
“blinded” with respect to the order of tape presentation. As 
before, we used the numerical scoring system of Tsui and 
colleagues { l}: 
T = [(R + L + E) X D,} + [U X D,], 
where T is total score, R is rotation (0 = absent, 1 = <15”, 
2 = 15” to SO”, 3 = >30”); L is lateral head tilt (0 = 
absent, 1 = mild, 2 = moderate, 3 = severe); E is shoulder 
elevation or depression (0 = absent, 1 = mild, 2 = severe); 
U is unsustained movement, such as tremor or jerk (0 = 
absent, 1 = present); and D, and D, are the durations of 
sustained and unsustained movements, respectively (1 = in- 
termittent, 2 = continuous). The same scoring system was 
also used to evaluate the patients at each clinic visit to deter- 
mine whether any objective benefit from a previous injection 
persisted. As in our previous study, changes in objective 
score of at least 3 points were considered to be “substantial.” 
Electvophysiological Techniques 
Each patient was evaluated electrophysiologically at the time 
of entry into the study and again 4 to 8 weeks after the final 
injection (in 1 patient, che follow-up EMG was performed 1 
week after the final injection, and in 2 patients, it was per- 
formed 4 weeks after the third injection). A six-channel 
EMG recording was collected on a polygraph, with three 
muscle pairs being studied. Surface electrodes were used to 
record the activity of the trapezius and sternocleidomastoid 
muscles on each side, and monopolar needle electrodes were 
used to record activity of the splenius capitis muscles in refer- 
ence to surface electrodes placed over the C7 spinous pro- 
cess. Recordings were made on  all patients while they were 
sitting erect, with the head in the spontaneously abnormal 
position, and then also with the head maintained facing for- 
ward so that the torticollis was rcsisted voluntarily for approx- 
imately 30 seconds. All six muscles were studied in every 
patient at each session, regardless of the number of muscles 
injected. Clearly, it would be optimal to study even deeper 
muscles as well, but this is not practical in human subjects. 
Our goal was not to define the precise pattern of muscle 
activity responsible for the abnormal neck posture, but to 
determine whether the pattern changed after botulinum 
toxin injections. 
Because equipment to rectify and integrate the EMG was 
not available to us, we devised a descriptive scoring system 
to grade the level of muscle activity. Thus, each muscle’s 
interference pattern was graded on a scale of 0 to 3 to give 
each muscle an EMG score. A score of 3 was assigned when 
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NA = not applicable (objective response defined as change from placebo score). 
the EMG recording consisted of a nearly full interference 
pattern in which individual motor-unit discharges could not 
be recognized. A score of 2 was assigned if the EMG record- 
ing consisted of an interference pattern in which motor units 
continuously disrupted the baseline but in which individual 
motor units were often seen. A score of 1 was assigned if 
the EMG recording reflected nearly continuous recruitment 
of individually recognizable motor units that did not continu- 
ously disrupt the baseline. A score of 0 was assigned if indi- 
vidually recognizable motor units were not activated or were 
activated less than 10% of the time. A muscle assigned a 
score of 3 always had more promincnt motor-unit activation 
than the corresponding muscle on the contralateral side. 
Scores were generally based on the activity recorded while 
the head was maintained facing forward. However, when the 
sternocleidomastoid corrected an abnormal head rotation or 
the ipsilateral sternocleidomastoid-splenius capitis pair cor- 
rected a contralateral head tilt, scoring of these muscles was 
undertaken when the head was in the spontaneously abnor- 
mal position. This was done to minimize any artifact due 
to voluntary activity of neck muscles compensating for the 
abnormal head position. 
Three patients with torticollis who had never received in- 
jections of botulinum toxin served as control subjects for 
the electrophysiological studies, undergoing EMGs on two 
occasions 1 month apart. 
Results 
Clinical Response 
The subjective and objective response rates (Table 1) 
were very similar to those found previously. Of the 
22 patients who entered the study, 77% (17 patients) 
showed subjective improvement, substantial in 64% 
(14 patients). The corresponding numbers in our 
earlier study {8] were 80% (16 patients) and 55% 
( 1  1 patients). Objective improvement (based on the 
“blinded” scores assigned at videotape review) was 
more frequent in the current study than previously, 
with 7 of the 22 enrolled patients (32%) showing sub- 
stantial objective improvement, as opposed to 15% 
(3 patients) in our prior study. Even so, this higher 
objective improvement rate was still not statistically 
significant for any individual toxin dose (p > 0.05, Wil- 
coxon signed rank test). However, when a composite 
“treatment score” (the average of the three scores cor- 
responding to the three different toxin doses) was com- 
pared with a “control score” (the average of the score 
at baseline and the score after placebo injection) for 
each patient, the objective improvement was statisti- 
cally significant (p < 0.01, Wilcoxon signed rank test), 
in constrast to our previous study. This discrepancy 
between results using the composite treatment score 
and scores for individual toxin doses is apparent from 
inspection of Table 2: in 18 patients, the composite 
treatment score was lower (“better”) than the control 
score, and in 2 patients, it was higher. For the lowest 
dose, scores fell for 10 patients and rose for 6; for the 
intermediate dose, scores fell for 11 patients and rose 
for 5 ;  and for the highest dose, scores fell for 11 pa- 
tients and rose for 4. 
Side effects and duration of action were similar to 
our previously published results: subjective benefit 
typically lasted 1 to 3 months, and the most commonly 
reported adverse effects were local pain (either at the 
injection sites or “strain” in nearby muscles), local 
weakness, and dysphagia. 
Electromyographic Results 
As expected, the EMG score of individual muscles 
changed after patients received the full course of botu- 
linum toxin injections. The change in EMG score be- 
tween baseline and follow-up studies for a given mus- 
cle was clearly related to the dose of botulinum toxin 
that had been injected into that muscle (Fig). Although 
the EMG scores were descriptive, they were assigned 
by an investigator who did not know which muscles 
had been injected, or the doses used, so this relation- 
ship was not due to biased scoring. 
The relationship between dose and change in EMG 
score is also evident from Table 3. Of the muscles 
injected with a base dose of 40 units or  more, 81% of 
muscles showed a decrease in EMG activity, whereas 
only 39% of muscles injected with a base dose of 20 
units or less did so. By contrast, among noninjected 
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Table 2. Objectipe Scoresfor All Patients Baed on Videotape Review 
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”The composite treatment score is the mean of the scores corresponding to the three different doses of botulinum toxin. 
bThe control score is the mean of the score at baseline and the score after placebo injection. 
NA = not available (patient missed the videotape session or tape was lost). 
loo 1 
0 - Average dose for gwen 
change in EMG score 
80 
-3.0 -2.0 -1.0 0.0 1.0 2.0 
Change in EMG Score 
Change in E M G  score @retreatment score subtracted from Jcore 
after treatment) plotted against the base d a ~ e  of botulinum toxin 
injected. A negative value rejects a reduction in EMG activity 
for that muscle. The shaded squares represent the mean base dose 
for a given change in E M G  score. 
muscles, an increase in EMG score occurred more 
commonly than did a decrease. In fact, over one-fourth 
(27%) of noninjected muscles showed an increase in 
EMG activity, as opposed to only 6% of injected mus- 
cles. This difference was statistically significant ( z  score 
for the difference between proportions, z = 3.14, 
p < 0.01). 
Given the known mechanism of action of botulinum 
toxin at the neuromuscular junction, it should not be 
surprising to see a reduction in EMG score and a corre- 
lation with dose soon after an injection of botulinum 
toxin. However, this result would not necessarily be 
expected in the 6 patients who had received placebo 
injections at the final session. Since the study design 
required that all subjective and objective benefits of an 
injection session should have disappeared before the 
next injection session could take place, the follow-up 
EMG study in these patients (performed 2 to 5 months 
after the last injection of botulinum toxin) should not 
have reflected the acute effects of the toxin. Yet, even 
for these patients, injected muscles showed a reduction 
in EMG score (Table 4). It is unlikely that the placebo 
injections were somehow acting as a “conditioned stim- 
ulus,” since so few patients showed substantial clinical 
improvement from placebo. Again, 27% of nonin- 
jected muscles showed an increase in EMG activity. 
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Table 3. Changes in E M G  Activity in Muscles Injected with Different Base Do.rey of Botulinum Toxin" 
Total No. of 
Muscles 
No. of Muscles 
with Decreased 
EMG Activity 




Dose 2 40 units 
0 < dose 5 20 units 
Dose = 0 





aThe base dose was the intermediate dose injected into each muscle. At separate sessions, injections of half the base dose and twice rhe base 
dose were also administered. The follow-up EMG was performed after all injection sessions had been completed (with two exceptions; see text 
for details). 
Table 4. Comparison of E M G  Findings Following Injection afHzgh Dose of Botulinum Toxin u i th  Those Fotlowing Injection of  Placebo 
No. of Muscles 
Muscles EMG Activitv EMG Activitv 
No. of Muscles 
Total No. of with Decreased with lncveaed 
Injected muscles: highest dose last 
Noninjected muscles: placebo lasta 11 
19 
Injected muscles: placebo lasP 25 
13 (68%) 
9 (36%) 
1 ( 9 % )  
"For patients who received their placebo injections 4 weeks before the EMG, the EMG findings in injected muscles and noninjected muscle5 
are shown. 
Thus, even after the original, abnormal head position 
had returned (and clinical examination showed normal 
muscle strength), EMG recordings still indicated a 
change from the baseline pattern of muscle activity. 
The same conclusion follows from a consideration 
of those patients who failed to show substantial clinical 
improvement. Of the 13 patients who did not show 
substantial objective improvement with any dose, 11 
nevertheless showed a convincing change in the pat- 
tern of EMG activity, defined as a change in EMG 
score in at least three muscles. In 7 of these patients, 
the most active muscle (based on EMG scores) before 
the injections was no longer the most active muscle 
after the injections. Similarly, there was a change in 
the most active muscle identified by EMG studies in 5 
of the 6 patients who did not report substantial subjec- 
rive improvement with any dose. 
In contrast, in the 3 untreated control patients with 
torticollis, only 1 (8%) of 12 muscles studied showed 
a reduction in EMG activity, and 1 muscle showed an 
increase in activity. 
Discussion 
This study corroborates our earlier results and those 
of other investigators {1-8), providing further evi- 
dence for the efficacy of local injections of botulinum 
toxin in the treatment of torticollis. As before, we were 
unable to show a statistically significant change in ob- 
jective scores for any individual toxin dose, but we 
attribute this failure to the insensitivity of the scoring 
system, as we discussed previously E8, 143. Similar 
problems are associated with the use of other scoring 
systems. Despite its limitations, we have continued to 
use this scoring system because it provides an objective 
measure by whch our results can be compared with 
our previous results and those of other authors. 
The main purpose of the current study was to com- 
pare the pattern of muscle activity before and after a 
series of injections of botulinum toxin. As expected, 
patients showed a general depression of EMG activity 
in injected muscles soon after the injections had taken 
place. The magnitude of this depression correlated 
with the dose of toxin injected. This depression of 
EMG activity persisted even after the clinical effects of 
the injections had disappeared (as shown by the pa- 
tients who received placebo at their final injection ses- 
sions). Moreover, there was a tendency for muscles 
that had not been injected to show increased EMG 
activity, and this effect, too, was seen in patients who 
received placebo at their final injection session. With 
only one exception, these patients did not report any 
change from their baseline head position, and none 
was evident on examination (based on the numerical 
scoring system). Thus, the same abnormal head posi- 
tion was now associated with a different pattern of 
muscle activity. It is unlikely that this represents an 
inherent variability in muscle activity in patients with 
torticollis, or lack of reproducibility in our EMG scor- 
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ing system, since untreated patients showed minimal 
change in muscle activity over time. 
One might have expected that patients who failed to 
demonstrate a substantial clinical benefit from any of 
the injections would also fail to show an appreciable 
change in the pattern of muscle activity, since their 
abnormal head position remained constant throughout 
the study. Contrary to this expectation, a change in the 
pattern of muscle activity was evident in these patients 
as well. This was not simply an unmasking of muscles 
previously active at a low level, for the EMG scores 
revealed increased activity in individual muscles in the 
majority of these patients. 
It is difficult to account for all of these findings 
purely on the basis of the direct effects of botulinum 
toxin at the neuromuscular junction. It is conceivable 
that the persistence of EMG changes beyond the dura- 
tion of clinical response could simply mean that the 
EMG is more sensitive than clinical observation; the 
EMG changes in patients who never demonstrated any 
clinical change might be interpreted in this way also. 
However, the inmared EMG activity in noninjected 
muscles in both of these groups of patients suggests a 
central, rather than a peripheral reorganization. 
Were it not for this increase in EMG activity in non- 
injected muscles, our results could be questioned on 
methodological grounds. We recorded EMG activity 
in two head.positions, and chose to base our scoring 
system primarily on the EMG activity recorded with 
the head maintained facing forward because it is the 
more useful one for assessing the muscles that move 
the head away from a normal position. Some of the 
EMG activity recorded with the head facing forward 
may have reflected compensatory activity of muscles 
not directly involved in producing the abnormal head 
position. We tried to correct for this (as discussed in 
the Material and Methods section), but if our correc- 
tion was not sufficient, some of the reduction in EMG 
activity seen after injections of botulinum toxin may 
simply have reflected a reduction in this compensatory 
muscle activity. This interpretation cannot explain all 
of our results, however. Since injected muscles were 
always chosen as the ones whose action contributed to 
moving the head from the forward to the spontane- 
ously abnormal position, the weakness of the injected 
muscles should always have made it easier for other 
muscles to maintain the head in a forward position. 
While this could result in reduced EMG activity being 
recorded from these muscles, there is no reason to 
expect increased activity in any muscles on this basis. 
Because we studied activity in only six muscles, with 
the neck in only two positions, the present study does 
not allow us to draw any conclusions regarding the 
nature of the motor program itself. It is conceivable, 
in fact, that head position is controlled by more than 
one motor program. For example, one program might 
control tonic activation of neck muscles while another 
could be related to changes in head position (analogous 
to the control system for saccadic eye movements). 
Obviously, more detailed observations would be nec- 
essary to investigate these issues. However, our obser- 
vations were sufficient to demonstrate that the pattern 
of muscle activity changed after injections of botuli- 
num toxin, and th s  was at least partly due to central 
reorganization. 
As discussed in the introduction, this conclusion is 
consistent with the idea that torticollis results from an 
abnormal motor program. When the most active mus- 
cles are functionally denervated by local administration 
of botulinum toxin, this “program” may simply call on 
other muscles to achieve its ends. This conclusion also 
follows from the results of surgical series, where the 
abnormal head position eventually recurs despite selec- 
tive rhizotomy, peripheral nerve section, or muscle 
section t l 5 ,  163. 
If other muscles can indeed substitute for the in- 
jected muscles to produce the abnormal head position, 
it might be expected that all patients will eventually 
fail to benefit from repeated injections of botulinum 
toxin. However, this has not been our experience, nor 
that of other investigators 131. Whereas some patients 
gradually lose their response to botulinum toxin, oth- 
ers continue to experience satisfactory results for at 
least several years. This may simply reflect a slower 
adaptation rate, and with continued follow-up these 
patients may also ultimately fail to respond to repeated 
injections. Alternatively, there may be two distinct cat- 
egories of patients with torticollis, possibly reflecting 
separate pathogenetic mechanisms, or perhaps varia- 
tions between patients in the degree to which their 
motor programs adapt to environmental perturbations. 
Those patients in whom the abnormal motor program 
produces relatively selective overactivity of certain 
muscles might experience persistent benefit from re- 
peated injections. By contrast, for patients in whom 
the motor program abnormality is less dependent on 
the activity of any particular neck muscle, functional 
(or actual) denervation might be followed by a fairly 
rapid emergence of a new pattern of muscle activity. 
The present study was not designed to address these 
issues, which remain speculative, but one clear practical 
result does emerge. We have demonstrated that the 
pattern of muscle activity in patients with torticollis 
may change after injections of botulinum toxin, and 
this should be suspected in patients who initially re- 
sponded to injections but subsequently fail to do so. 
This issue could not be addressed directly in the pres- 
ent study, since each patient received a different dose 
of botulinum toxin at each injection session. An appar- 
ent reduction in efficacy could therefore have been a 
function of the change in dose. However, in patients 
who fail to respond to previously effective doses, we 
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recommend performing EMG studies to identify the 
most active muscles, and adjusting injection sites ac- 
cordingly. 
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